Novartis AG (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 161   

Articles published

NVS 75.54 -0.35 (-0.46%)
price chart
Novartis AG (ADR) (NVS) Multiple Sclerosis Molecule: Ray of Hope
Novartis AG (ADR) (NYSE:NVS) investigational molecule for the treatment and management of multiple sclerosis has shown remarkable reduction in the disease progression up to 21%.
Novartis AG (ADR) (NYSE:NVS): Reviewing Earnings Estimates
Novartis AG (ADR) (NYSE:NVS) soared 0.51% or +0.42 points during previous trade after opening at the price of $81.92, a total of 1.58M shares exchanged hands compared with its average trading volume of 1.71M shares.
Novartis AG (ADR) 17% Potential Upside Now Implied by Chardan Capital Markets
Novartis AG (ADR) with TICKER NYSE:NVS has had its stock rating noted as 'Initiated' with the recommendation being set at 'BUY' yesterday by analysts at Chardan Capital Markets.
Will Novartis AG (ADR) (NVS) Cosentyx Lead Psoriasis Therapeutic Market?
Keeping in view fierce competition in the future as well as the patent cliff side effects, Novartis AG (ADR) (NYSE:NVS) is working on its blockbuster molecule Cosentyx to be the market leader in the management and treatment of psoriasis.
Novartis AG (ADR) (NYSE:NVS) Stops Phase III Trial of Arzerra for Pemphigus ...  Thorold News
Bimagrumab (BYM338) drug from Novartis AG (ADR) (NYSE:NVS) Failed a Phase ...
Notable 13F Reporting: Fort Washington Investment Advisors INC Upped Its ...
The company was downgraded on Tuesday, April 12 by Morgan Stanley. Mainfirst downgraded the shares of NVS in a report on Wednesday, October 28 to “Underperform” rating.
Can Novartis AG (ADR) (NVS) Survive with Alcon Crisis?
Novartis AG (ADR) (NYSE:NVS) is considering the sale of its eye care division, Alcon, due to its revenue decline in the last two years.
Regulatory Filing: Bryn Mawr Trust Company Trimmed Its Novartis Ag Sponsored ...
Bryn Mawr Trust Company decreased its stake in Novartis Ag Sponsored Adr (NVS) by 68.65% based on its latest 2016Q2 regulatory filing with the SEC.
Amgen, Inc. (AMGN) and Novartis AG (ADR) (NVS) Erenumab: New Hope for Migraine ...
Amgen, Inc. (NASDAQ:AMGN) has announced that erenumab clinical results for the management and treatment of chronic migraine headaches have met the primary endpoints.
Novartis Reports Positive Phase II Data on Migraine Drug  Nasdaq
Holder Worth Mentioning: Fort Washington Investment Advisors INC Boosted Its ...
More news for Novartis AG (ADR) (NYSE:NVS) were recently published by:, which released: “Can Novartis AG (ADR) Reach Financial Stability via Restructuring?” on May 20, 2016.'s article titled: ...
Today's Rating Alert: Chardan Capital Markets Maintains a "Buy" ...  Thorold News
Novartis AG (ADR) (NVS) is Reiterated by Chardan Capital Markets to Buy ...  Market Digest
How Many Heart Failure Deaths Can Novartis AG (ADR) (NYSE:NVS) Entresto Reduce?
A fresh analysis of Novartis AG (ADR) (NYSE:NVS) drug Entresto has shown that it can significantly reduce heart failure deaths.